UTUnited Therapeutics UTHR · NASDAQ
$598.72 +0.87% (+$5.18)
- Market cap
- $25.5B
- Enterprise value
- $23.7B
- P/E
- 19.4x
- Forward P/E
- 20.3x
- PEG
- 1.6x
- P/S
- 8.1x
- P/FCF
- 23.3x
- EV/EBITDA
- 14.3x
- ROIC
- 17.7%
- Gross margin
- 86.1%
- Net margin
- 41.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -1.1x
- Beta
- 0.56
- Free float
- 91.4%
About the company
United Therapeutics Corporation is an American biotechnology company headquartered in Silver Spring, Maryland. The company focuses on the development and manufacturing of drugs for the treatment of pulmonary arterial hypertension and other pulmonary and vascular-related diseases. Their main drugs include therapies for the treatment of pulmonary arterial hypertension and carcinoid syndrome. United Therapeutics is also involved in research and development of new drug formulations in the field of regenerative medicine and organ transplantation. The company is known for its innovative approach to treating pulmonary diseases and comprehensive research in the field of biotechnology. Shares of United Therapeutics Corporation are publicly traded on the NASDAQ stock exchange.
Sector
Healthcare
Industry
Biotechnology
CEO
Martine A. Rothblatt
Employees
1,400
Headquarters
Silver Spring
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Earnings per share grew by 23% a year over the last 3 years.
- What to watch: It missed profit estimates 4 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 42 USD is left as net profit.
- What speaks for it: It earns 18 USD a year on every 100 USD of invested capital.
Financial health
Can it carry its debt?
- What speaks for it: It has no debt and holds $1.80B in cash.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number